FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Executive Summary
Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said